8. Jan 2016 – Name of guideline

**PICO (2.1)**

Population: Some population

Intervention: Some intervention

Comparator: Some comparator

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome**Timeframe | **Study results and measurements** | **Absolute effect estimates** | **Certainty in effect estimates**(Quality of evidence) | **Summary** |
| Comparator  | Intervention |
| DVTOver 5 weeks | Relative risk: 0.44(CI 95% 0.32 – 0.65)Based on data from 12.698 patients in 22 studies | 200per 1000 | 300per 1000 | **Moderate**Some comment that is describing the quality | Some summary |
| Difference: 25 fewer per 1000(CI 95% 31 fewer – 22 fewer) |
| DVTOver 5 weeks | Measured by: VASScale: 1-10 Lower betterBased on data from 12.698 patients in 22 studies | 0.34(mean) | 0.87(mean) | **Moderate**Some comment that is describing the quality | Some summary |
| Difference: MD 0.25 lower(CI 95% 31 lower – 22 lower) |
| DVTOver 5 weeks | Based on data from 12.698 patients in 22 studies | Some text | **Moderate**Some comment that is describing the quality | Some summary |

**References**

[1] Authors1. Title1. The citation details1

[2] Authors2. Title2. The citation details2

**Summary**

The summary text